Work

ORAL ABSTRACT: ALL-1317: Outcomes After TKI Discontinuation in Patients With Ph+ ALL Treated With Blinatumomab and Ponatinib

Year: 2026

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)00354-x

Authors: Abigail Huetteman, Amin Azem, Daniel Walgenbach, Katherine Tobon, Ziad Abuhelwa, Kriti Gera, Leidy Isenalumhe, Jennifer Eatrides, Julio Chavez, Bijal Shah

Institutions: University of South Florida, Moffitt Cancer Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7204696544

FWCI:

Cites:

Cited by:

Related to: 10